News

Biolex is co-developing Locteron in collaboration with drug delivery and development company OctoPlus, initially for the treatment of patients with chronic hepatitis C. Locteron combines BLX-883, a recombinant

DepoBupivacaine is SkyePharma’s novel sustained-release injectable formulation of the local anaesthetic bupivacaine and is designed to provide localized pain relief for more than 48 hours after a surgical

Following clearance, Alnylam plans to initiate a phase I safety study in healthy adult volunteers, representing the first program the company will have advanced to human clinical trials.

AGS-PSCA is a fully human monoclonal antibody directed to Agensys’ proprietary target prostate stem cell antigen (PSCA), an antigen expressed at significant levels on tumor cells from the

Additionally, there will be no refrigeration requirements for the tablets, benefits not available with the old Kaletra capsules. The FDA approval of the Kaletra tablet formulation was based

The drug has received the designation as it has potential to treat a disorder that affects less than 200,000 people in the US. The status confers several benefits

The FDA grants priority review status to products that are considered to be potentially significant therapeutic advancements over existing approved therapies in the treatment, diagnosis or prevention of

The companies have signed separate royalty free license agreements with the International Partnership for Microbicides (IPM) that will allow the organization to develop the compounds as vaginal gels

The trial, which involved nearly 300 patients, was aimed at evaluating the safety and efficacy of locally administered 17beta-estradiol, the most potent estrogen. The study monitored its ability